Form 4: Pfizer SVP & Controller Jennifer B. Damico Reports Stock and Rights Grants

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reports the acquisition of restricted stock units and stock appreciation rights.

Summary

• On February 27, 2024, Jennifer B. Damico, SVP & Controller of Pfizer Inc., reported transactions involving Pfizer's common stock.
• Damico acquired 5,113 shares of common stock through the grant of restricted stock units at a price of $0.00.
• Following this transaction, Damico directly owns 13,495 shares of Pfizer common stock.
• Damico also acquired 19,697 stock appreciation rights (SARs) exercisable on February 27, 2029, and 17,404 SARs exercisable on February 27, 2031, both with an exercise price of $26.89.
• These SARs will be settled in shares of Pfizer common stock upon vesting.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of executive compensation, which is neither particularly positive nor negative.

Positives

• The grant of restricted stock units and stock appreciation rights to a key executive like the SVP & Controller can be seen as an incentive to align their interests with the long-term performance of the company.

Future Outlook

The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth and seventh anniversary of the grant date, contingent on vesting requirements.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Grants of stock and stock options are common compensation practices in the pharmaceutical industry to incentivize executives.

Comparison to Industry Standards

• Stock grants and options are a standard component of executive compensation packages in the pharmaceutical industry, aligning management's interests with shareholder value.
• Companies like Johnson & Johnson, Merck, and AbbVie also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The grants align executive interests with shareholder value, potentially incentivizing decisions that benefit shareholders in the long term.

Key Dates